Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. USO
7. META
8. LMT
9. NVDA
10. TLT

Go back to Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 5c

March 8, 2021 4:16 PM EST

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.44), $0.05 better than the analyst estimate of ($0.49).

"We expect 2021 will be a year of immense progress across our two highly promising programs aimed at addressing key areas of unmet need, coupled with a sharp focus on pipeline expansion," said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. "Notably, we plan to present data from the Phase 1 portion of our ongoing AUGMENT-101 trial of SNDX-5613,... More